← All DEA Flashcard Decks

DEA Controlled Substance Schedules Flashcards

7 cards from real DEA practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 7 DEA Controlled Substance Schedules flashcards as text
  1. Which schedule of drugs has the highest potential for abuse among those with accepted medical use?

    Answer: Schedule II

    Schedule II drugs have the highest abuse potential of substances that still have accepted medical uses.

  2. A pharmacist receives a prescription for a Schedule II opioid faxed from a prescriber. This fax is generally valid only as what?

    Answer: Advance notice requiring the original written prescription

    A faxed Schedule II prescription generally serves as notice; the original signed prescription is required before dispensing (with limited exceptions).

  3. Which of these drugs is classified in Schedule IV?

    Answer: Tramadol

    Tramadol is a Schedule IV controlled substance with lower abuse potential than Schedule II opioids.

  4. GHB, when marketed as the prescription drug sodium oxybate (Xyrem), is placed in which schedule?

    Answer: Schedule III

    As an approved prescription product, sodium oxybate is Schedule III, while illicit GHB is Schedule I.

  5. What is the primary purpose of the DEA scheduling system?

    Answer: To regulate manufacture, distribution, and dispensing based on abuse potential

    The scheduling system controls the manufacture, distribution, and dispensing of substances according to abuse and dependence potential.

  6. In some states, Schedule V cough syrups with codeine may be dispensed under what condition?

    Answer: Without a prescription under limited circumstances

    Certain Schedule V preparations may be sold without a prescription under limited state-permitted circumstances with recordkeeping.

  7. Which factor distinguishes Schedule III from Schedule II drugs?

    Answer: Schedule III has moderate-to-low physical dependence potential

    Schedule III drugs carry a moderate to low risk of physical dependence, lower than Schedule II.